Affordable Access

Publisher Website

Fixed Combination for the Treatment of Dyslipidaemia.

Authors
  • Ferri, Nicola1, 2
  • Ruscica, Massimiliano3, 4
  • Santos, Raul D5, 6
  • Corsini, Alberto3
  • 1 Department of Medicine (DIMED), University of Padova, Via Giustiniani 2, 35128, Padua, Italy. [email protected]. , (Italy)
  • 2 Veneto Institute of Molecular Medicine (VIMM), Via Orus 2, 35129, Padua, Italy. [email protected]. , (Italy)
  • 3 Department of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", University of Milan, 20133, Milan, Italy. , (Italy)
  • 4 Department of Cardio-Thoracic-Vascular Diseases - Foundation IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy. , (Italy)
  • 5 Lipid Clinic, Heart Institute (InCor), University of São Paulo, São Paulo, Brazil. , (Brazil)
  • 6 Hospital Israelita Albert Einstein, São Paulo, Brazil. , (Brazil)
Type
Published Article
Journal
Current Atherosclerosis Reports
Publisher
Springer-Verlag
Publication Date
Oct 01, 2023
Volume
25
Issue
10
Pages
691–699
Identifiers
DOI: 10.1007/s11883-023-01142-x
PMID: 37715044
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

It is clear from epidemiological studies that patients at high and very-high risk of atherosclerotic cardiovascular diseases (ASCVD) risk do not reach lipid guideline-recommended targets. Thus, fixed-dose combinations of statins/ezetimibe, bempedoic acid/ezetimibe and statins/fibrates may represent a further armamentarium in the field of lipid-lowering approaches in these individuals. The combination therapy of moderate-intensity statin with ezetimibe is not inferior to high-intensity statin monotherapy in reducing cardiovascular outcomes. Drug discontinuation or dose reduction is inferior with fixed-dose combination. The fixed-dose combination of bempedoic acid with ezetimibe is superior to bempedoic acid in monotherapy in lowering LDL-C and in reducing high-sensitivity C-reactive protein concentrations. The combination fenofibrate with atorvastatin is superior to monotherapies in lowering triglycerides. Lipid-lowering fixed-dose combinations may guarantee a higher therapy adherence, representing a better approach to control plasma lipids and thus ameliorate ASCVD burden. Additional studies will define the advantages on cardiovascular outcomes in high and very high-risk patients. © 2023. The Author(s).

Report this publication

Statistics

Seen <100 times